Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Hopper

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
JACC. Heart Failure|August 8, 2015
The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure TrialsHenry Krum, Ingrid Hopper
Heart, Lung & Circulation|July 12, 2014
Statins in CHFHenry Krum, Ingrid Hopper
Australian Prescriber|September 27, 2017
Chronic heart failureIngrid Hopper, Kellie Easton
Cardiovascular Therapeutics|October 7, 2014
Celiac disease and drug absorption: implications for cardiovascular therapeuticsIan Wang, Ingrid Hopper
Australian Prescriber|December 10, 2015
Warfarin brandsLinda Graudins, Fiona Chen, Ingrid Hopper
European Journal of Heart Failure|January 24, 2014
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunctionHannah Clark, Henry Krum, Ingrid Hopper
The Medical Journal of Australia|March 30, 2019
Qualified privilege legislation to support clinician quality assurance: balancing professional and public interestsSusannah Ahern, Ingrid Hopper, Erwin Loh
European Journal of Heart Failure|November 13, 2012
Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythmIngrid Hopper, Marina Skiba, Henry Krum
International Journal of Cardiology|December 3, 2014
Neprilysin inhibitors preserve renal function in heart failureFiona Bodey, Ingrid Hopper, Henry Krum
The Medical Journal of Australia|June 2, 2017
Clinical quality registries for clinician-level reporting: strengths and limitationsSusannah Ahern, Ingrid Hopper, Susan M Evans
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
JACC. Heart Failure|August 8, 2015
The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure TrialsHenry Krum, Ingrid Hopper
Heart, Lung & Circulation|July 12, 2014
Statins in CHFHenry Krum, Ingrid Hopper
Australian Prescriber|September 27, 2017
Chronic heart failureIngrid Hopper, Kellie Easton
Cardiovascular Therapeutics|October 7, 2014
Celiac disease and drug absorption: implications for cardiovascular therapeuticsIan Wang, Ingrid Hopper
Australian Prescriber|December 10, 2015
Warfarin brandsLinda Graudins, Fiona Chen, Ingrid Hopper
European Journal of Heart Failure|January 24, 2014
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunctionHannah Clark, Henry Krum, Ingrid Hopper
The Medical Journal of Australia|March 30, 2019
Qualified privilege legislation to support clinician quality assurance: balancing professional and public interestsSusannah Ahern, Ingrid Hopper, Erwin Loh
European Journal of Heart Failure|November 13, 2012
Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythmIngrid Hopper, Marina Skiba, Henry Krum
International Journal of Cardiology|December 3, 2014
Neprilysin inhibitors preserve renal function in heart failureFiona Bodey, Ingrid Hopper, Henry Krum
The Medical Journal of Australia|June 2, 2017
Clinical quality registries for clinician-level reporting: strengths and limitationsSusannah Ahern, Ingrid Hopper, Susan M Evans
Pageof 11